Childhood and early-onset schizophrenia - NeuRA Library

Childhood and early-onset schizophrenia

What is childhood and early-onset schizophrenia?

Childhood-onset schizophrenia has an onset prior to the age of 13 years, and early-onset schizophrenia has an onset between the ages of 13 and 17 years.

What is the evidence on childhood and early-onset schizophrenia?

Moderate quality evidence suggests poorer long-term functioning in children and adolescents with early-onset schizophrenia compared to other psychiatric disorders.

August 2020

Image: ©Brian Jackson – Fotolia – stock.adobe.com

Last updated at: 4:18 am, 30th August 2021

To view documentation related to this topic download the files below
Fact Sheet Technical Commentary

Tags: Children and adolescents

NeuRA Libraries

Title Colour Legend:
Green - Topic summary is available.
Orange - Topic summary is being compiled.
Red - Topic summary has no current systematic review available.

RELATED TOPICS

Therapies for childhood onset and early onset schizophrenia

What is childhood and early-onset schizophrenia? Childhood-onset schizophrenia is defined as schizophrenia with onset prior to the age of 13 years, and early-onset schizophrenia describes schizophrenia between the ages of 13 and 17 years. What is the evidence for psychosocial treatments for childhood and early-onset schizophrenia? Moderate quality evidence finds supportive therapy is better than cognitive behavioural therapy for improving symptoms, however cognitive behavioural therapy is better than supportive therapy for improving insight in children with early-onset schizophrenia. Education about the illness may be beneficial for improving symptoms and functioning. Moderate to low quality evidence finds cognitive remediation can improve…

Medications for childhood and early-onset schizophrenia

What is childhood and early-onset schizophrenia? Childhood-onset schizophrenia is defined as schizophrenia with onset prior to the age of 13 years, and early-onset schizophrenia describes schizophrenia onset between the ages of 13 and 17 years. What is the evidence for pharmaceutical treatments for childhood and early-onset schizophrenia? Compared to first-generation antipsychotics, moderate quality evidence finds a small to medium-sized benefit of second-generation antipsychotics for global and mental state in children and adolescents with schizophrenia. There was greater improvement with standard dose than low-dose antipsychotics, although there are more side effects with standard doses. Moderate quality evidence finds clozapine was the…